$5.62
2.18% yesterday
Nasdaq, Oct 13, 10:00 pm CET
ISIN
US48576U1060
Symbol
KPTI

Karyopharm Therapeutics, Inc. Stock price

$5.62
-0.64 10.22% 1M
+1.41 33.49% 6M
-4.52 44.60% YTD
-7.13 55.92% 1Y
-71.18 92.68% 3Y
-230.63 97.62% 5Y
-158.48 96.58% 10Y
-235.13 97.67% 20Y
Nasdaq, Closing price Mon, Oct 13 2025
+0.12 2.18%
ISIN
US48576U1060
Symbol
KPTI
Industry

Key metrics

Basic
Market capitalization
$48.7m
Enterprise Value
$253.5m
Net debt
$204.8m
Cash
$51.7m
Shares outstanding
8.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.4 | 0.3
EV/Sales
1.9 | 1.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-113.1%
Return on Equity
41.1%
ROCE
-2,035.5%
ROIC
-235.1%
Debt/Equity
-1.1
Financials (TTM | estimate)
Revenue
$137.3m | $150.2m
EBITDA
$-114.9m | $-132.6m
EBIT
$-115.2m | $-104.4m
Net Income
$-123.6m | $-96.7m
Free Cash Flow
$-102.9m
Growth (TTM | estimate)
Revenue
-5.8% | 3.4%
EBITDA
12.1% | -11.3%
EBIT
12.0% | 12.6%
Net Income
-37.4% | -26.6%
Free Cash Flow
21.2%
Margin (TTM | estimate)
Gross
96.4%
EBITDA
-83.7% | -88.3%
EBIT
-83.9%
Net
-90.0% | -64.4%
Free Cash Flow
-75.0%
More
EPS
$-14.3
FCF per Share
$-11.9
Short interest
26.2%
Employees
279
Rev per Employee
$520.0k
Show more

Is Karyopharm Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,002 stocks worldwide.

Karyopharm Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Karyopharm Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
137 137
6% 6%
100%
- Direct Costs 4.98 4.98
14% 14%
4%
132 132
5% 5%
96%
- Selling and Administrative Expenses 111 111
9% 9%
81%
- Research and Development Expense 137 137
8% 8%
100%
-115 -115
12% 12%
-84%
- Depreciation and Amortization 0.32 0.32
6% 6%
0%
EBIT (Operating Income) EBIT -115 -115
12% 12%
-84%
Net Profit -124 -124
37% 37%
-90%

In millions USD.

Don't miss a Thing! We will send you all news about Karyopharm Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Karyopharm Therapeutics, Inc. Stock News

Neutral
PRNewsWire
6 days ago
– Transactions Provide Karyopharm with $100 Million of Financial Flexibility and Additional Capital – – Preliminary Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue for the Third Quarter of 2025 Expected to be in the Range of $42 to $44 Million and Approximately $32 Million, Respectively – – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – NEW...
Neutral
PRNewsWire
13 days ago
NEWTON, Mass. , Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee.
Neutral
PRNewsWire
about one month ago
– Top-Line Results Anticipated in March 2026 – NEWTON, Mass. , Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients.
More Karyopharm Therapeutics, Inc. News

Company Profile

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Head office United States
CEO Richard Paulson
Employees 279
Founded 2008
Website karyopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today